The role of Th17 cells in the pathogenesis of IBD has been documented in humans with active disease [5–7] and in mouse models in which disease severity was reduced by blockade or deficiency of IL-23 and/or IL-17 [8, 9]. This evidence concerns the gene IL17A and inflammatory bowel disease.